Acquiring Company
Fresenius SE & KGaA
Acquired Company
mAbxience
MadridMadridBiotechnologyHealth CareBiotechnologyDescription
Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% of mAbxience, marking the next phase in their growth journey. This follows a partnership that began in 2022 when Fresenius acquired a majority stake. With full ownership, Fresenius aims to enhance quality, innovation, and patient access to biosimilars. mAbxience will continue its commitment to existing customers and partners under the leadership of Jurgen van Broeck.
Fundz sees it the moment Fresenius SE & KGaA makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired mAbxience?
mAbxience was acquired by Fresenius SE & KGaA, based in Madrid. The deal was reported on October 1, 2026. Fresenius SE & Co. KGaA is a globally active healthcare group providing products and services for dialysis, the hospital, and outpatient medical care. Fresenius SE & KGaA is publicly traded (FSNUY) and operates in Biotechnology.
When did Fresenius SE & KGaA acquire mAbxience?
Fresenius SE & KGaA's acquisition of mAbxience was reported on October 1, 2026. Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% of mAbxience, marking the next phase in their growth journey. This follows a partnership that began in 2022 when Fresenius acquired a majority stake. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does mAbxience do?
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. It is privately held, operating in Biotechnology, and is based in Madrid.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.